Advertisement

Gene Mediated Anti-Cancer Strategies Involving the Vasculature

Inhibition of Angiogenesis and Vascular Targeting of Gene Therapy
  • Rhys T. Jaggar
  • Hock-Ye Chan
  • Adrian L. Harris
  • Roy Bicknell
Part of the NATO ASI Series book series (NSSA, volume 294)

Abstract

Recently, novel approaches to anti-cancer therapy have been described that involve gene transfer. These include anti-angiogenic strategies and vascular targeting of gene therapy.

Keywords

Thymidine Phosphorylase Cytosine Deaminase Packaging Cell Line Vascular Target Viral Producer Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aird. W.C., Jahroudi, N., Weiler-Guettlen H., Rayburn, H.B., and Rosenberg, R.D. Human von Willebrand factor gene sequences target expression to a subpopulation of endothelial cells in transgenic mice. Proc. Natl. Acad. Sci. USA, 92:4567–4571, 1995.PubMedCrossRefGoogle Scholar
  2. Borelli. E., Heyman, R., Hsi, M., and Evans, R.M. Targeting of an inducible toxic phenotype in animal cells. Proc. Natl Acad. Sci. USA, 85:7572–7576, 1988.CrossRefGoogle Scholar
  3. Burrows, F.J. and Thorpe, P.E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA, 90:8996–9000, 1993.PubMedCrossRefGoogle Scholar
  4. Clarke, M.S.F. and West, D.C. The identification of proliferation and tumor-induced proteins in human endothelial cells: a possible target for tumor therapy. Electrophoresis, 12:500–508, 1991.PubMedCrossRefGoogle Scholar
  5. Collins. T., Williams, A., Johnson, G.I., Kim, J., Eddy, R., Shows, T., Gimbrone Jr., M.A., and Bevilacqua, D.L. Structure and chromosomal location of the gene for endothelial-leukocyte adhesion molecule 1. J. Biol. Chem., 266:2466–2473, 1991.PubMedGoogle Scholar
  6. Denekamp, J. Endothelial cell proliferation as a novel approach to targeting tumor therapy. Br. J. Cancer, 45:136–139,1982.PubMedCrossRefGoogle Scholar
  7. Denekamp, J. and Hobson. B. Endothelial-cell proliferation in experimental tumors. Br. J. Cancer, 46:711–720, 1982.PubMedCrossRefGoogle Scholar
  8. Hurford Jr., R.K., Dranoff G., Mulligan, R.C., and Tepper, R.I. Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat. Genet., 10:430–435, 1995.PubMedCrossRefGoogle Scholar
  9. Lienard, D., Ewalenko, P., Delmotte, J.J., Renard, N., and Lejeune, F.J. High dose recombinant tumor necrosis factor a in combination with interferon γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol., 10:52–60, 1992.PubMedGoogle Scholar
  10. Millauer, B., Shawver, L.K., Plate, K.H., Risau, W., and Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature, 367:576–579, 1994.PubMedCrossRefGoogle Scholar
  11. Millauer, B., Longhi, M.P., Plate, K.H., Shawver, L.K., Risau, W., Ullrich, A., and Strawn, L.M. Dominant-negative inhibition of flk-1 suppresses the growth of many tumor types in vivo. Cancer Res., 56:1615–1620,1996.PubMedGoogle Scholar
  12. Miller, A.D., and Buttimore, C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol, 6:2895–2902, 1986.PubMedGoogle Scholar
  13. Montgomery, K.F., Osborn L., Hession, C., Tizard, R., Goff, D., Vassallo, C., Tarr, P.I., Bomsztyk, K., Lobb, R., Harlan, J.M., and Pohlman, T.H. Activation of endothelial leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Proc. Natl. Acad. Sci. USA, 88:6523–6527, 1991.PubMedCrossRefGoogle Scholar
  14. Mullen, C.A., Kilstrup, M., and Blaese, R.M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine — a negative selection system. Proc. Natl Acad. Sci. USA, 89:33–37, 1992.PubMedCrossRefGoogle Scholar
  15. Patterson, A.V., Zhang, H-T., Moghaddam, A., Bicknell, R., Talbot, D.C., Stratford, I.J., and Harris, A.L. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br. J. Cancer, 72:669–675, 1995a.PubMedCrossRefGoogle Scholar
  16. Patterson, C., Perrella, M.A., Hsieh, C-M., Yoshizumi, M., Lee, M-E., and Haber, E. Cloning and functional analysis of the promoter for KDR/flk-1: a receptor for vascular endothelial growth factor. J. Biol. Chem., 270:23111–23124, 1995b.PubMedCrossRefGoogle Scholar
  17. Russell, D.W., Berger, M.S., and Miller, A.D. The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Hum. Gen. Ther., 6:635–641, 1995.CrossRefGoogle Scholar
  18. Sato, N., Goto, T., Haranaka, K., Satomi, N., Nariuchi, H., Mano-Hirano, Y., and Sawasaki, Y. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J. Natl Cancer Inst., 76:1113–1121, 1986.PubMedGoogle Scholar
  19. Schweigerer, L., Malerstein, B., and Gospodarowicz, D. Tumor necrosis factor inhibits the proliferation of cultured capillary endothelial cells. Biochem. Biophys Res. Comm., 143:997–1004, 1987.PubMedCrossRefGoogle Scholar
  20. Welsh, R.M., Jensen, F.C., Cooper, N.R., and Oldstone, M.B.A. Inactivation of lysis of oncornaviruses by human serum. Virology, 74:432–440, 1975.CrossRefGoogle Scholar
  21. Yu, S.-F., Rueden, T., Kantoff, P.W., Garber, C., Seiberg, M., Ruether, U., Anderson, W.F., Wagner, E.F., and Gilboa, E. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA, 83:3194–3198, 1986.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Rhys T. Jaggar
    • 1
  • Hock-Ye Chan
    • 1
  • Adrian L. Harris
    • 1
  • Roy Bicknell
    • 1
  1. 1.Molecular Angiogenesis Group, Imperial Cancer Research Fund, Institute of Molecular MedicineUniversity of Oxford, John Radcliffe HospitalOxfordUK

Personalised recommendations